Enumeral
Enumeral was a Cambridge, Massachusetts-based biotechnology company which developed monoclonal antibody immunotherapies through an 'immunoprofiling' platform that allowed it to scan the human immune microenvironment and identify and validate potential drug candidates. The company filed for Chapter 11 bankruptcy and arranged to sell its assets to Xoma Corporation in January 2018.
| Company type | Public |
|---|---|
| OTCQB: ENUM | |
| Industry | Biotechnology |
| Founded | December 11, 2009 |
| Defunct | January 29, 2018 |
| Fate | Assets sold to Xoma Corporation during bankruptcy |
| Headquarters | , United States |
Key people | |
| Products | Monoclonal antibodies targeting immune checkpoint proteins |
Number of employees | 10 (2017) |
| Website | www |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.